Bryn Mawr Capital Management LLC Purchases 8,730 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Bryn Mawr Capital Management LLC raised its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 17.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 58,013 shares of the medical equipment provider's stock after purchasing an additional 8,730 shares during the quarter. Bryn Mawr Capital Management LLC's holdings in Zimmer Biomet were worth $6,566,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Dodge & Cox boosted its holdings in shares of Zimmer Biomet by 12.0% during the 4th quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider's stock valued at $2,019,480,000 after buying an additional 2,044,645 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Zimmer Biomet by 1.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,760,444 shares of the medical equipment provider's stock valued at $1,559,147,000 after buying an additional 176,337 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Zimmer Biomet by 398.7% during the 4th quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider's stock valued at $369,469,000 after buying an additional 2,796,372 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Zimmer Biomet by 7.6% during the 4th quarter. Northern Trust Corp now owns 2,370,224 shares of the medical equipment provider's stock valued at $250,367,000 after buying an additional 167,435 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Zimmer Biomet during the 4th quarter valued at $216,223,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Performance

Zimmer Biomet stock traded up $0.13 during midday trading on Tuesday, hitting $93.99. The stock had a trading volume of 2,348,608 shares, compared to its average volume of 1,830,884. The firm's fifty day moving average is $93.28 and its two-hundred day moving average is $101.18. The company has a market capitalization of $18.60 billion, a PE ratio of 20.79, a P/E/G ratio of 2.17 and a beta of 0.71. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.22 and a 52-week high of $116.71. The company has a current ratio of 2.44, a quick ratio of 1.46 and a debt-to-equity ratio of 0.53.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. The company had revenue of $1.91 billion during the quarter, compared to analyst estimates of $1.89 billion. Zimmer Biomet had a net margin of 11.86% and a return on equity of 12.73%. The firm's quarterly revenue was up 1.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.94 EPS. On average, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Thursday, June 26th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.02%. The ex-dividend date of this dividend is Thursday, June 26th. Zimmer Biomet's dividend payout ratio is 21.24%.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of the stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total transaction of $95,000.00. Following the completion of the sale, the insider directly owned 20,424 shares of the company's stock, valued at $1,940,280. This trade represents a 4.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.70% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. JPMorgan Chase & Co. dropped their price target on shares of Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 6th. Raymond James Financial lowered their target price on shares of Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. JMP Securities lowered their target price on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. Wells Fargo & Company lowered their target price on shares of Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Finally, Stifel Nicolaus set a $115.00 target price on shares of Zimmer Biomet and gave the company a "buy" rating in a research note on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat, Zimmer Biomet currently has a consensus rating of "Hold" and a consensus price target of $111.39.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.